CIMVF: AI 评分 56/100 — AI 分析 (4月 2026)

Pideka Group Inc., operating as Ikänik Farms, is a cannabis company involved in cultivation, production, distribution, and dispensary operations in California and Colombia. The company offers a range of cannabis products under various brands, targeting both scientific and commercial sales.

Key Facts: AI Score: 56/100 Sector: Healthcare

公司概况

概要：

Pideka Group Inc., operating as Ikänik Farms, is an integrated cannabis company focusing on cultivation, production, and distribution in California and Colombia. With a negative P/E ratio of -1.16 and a gross margin of 13.1%, the company competes in the specialty and generic drug manufacturing sector, offering products under the Ikanik, Essentials, Ronen, and Rations brands.

CIMVF是做什么的？

Ikänik Farms, Inc., operating as Pideka Group Inc. (CIMVF), is a vertically integrated cannabis company with operations spanning cultivation, production, distribution, and dispensary management. Founded with the vision of becoming a leading provider of pharmaceutical-grade cannabinoids, the company has established a presence in both California and Colombia. Ikänik Farms offers a diverse product portfolio, including pharmaceutical-grade cannabinoids, decarboxylated flower, finished CBD products, and finished ingredient cannabis oil, catering to scientific and commercial markets. These products are marketed under the brands Ikanik, Essentials, Ronen, and Rations. The company's operations in California focus on distribution and dispensary management, leveraging the state's established cannabis market. In Colombia, Ikänik Farms concentrates on cultivation and production, taking advantage of the country's favorable climate and regulatory environment for cannabis cultivation. This dual-market strategy allows the company to serve both domestic and international demand for cannabis products. Pideka Group Inc. is headquartered in Toronto, Canada, reflecting its strategic focus on international cannabis markets and its commitment to regulatory compliance and quality standards. The company aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain.

CIMVF的投资论点是什么？

Pideka Group Inc. (CIMVF) presents a speculative investment opportunity in the cannabis sector, characterized by high growth potential but also significant risks. With a current market capitalization of $0.00B and a negative P/E ratio of -1.16, the company's financial performance is under pressure, as reflected by a profit margin of -2220.5%. The company's gross margin stands at 13.1%. Key value drivers include expansion of its cultivation and production capabilities in Colombia, increased market penetration in California, and development of new cannabis-based products. Growth catalysts include evolving cannabis regulations in key markets and increasing consumer acceptance of cannabis products. However, potential risks include intense competition, regulatory uncertainties, and the company's current financial instability. Investors should carefully consider these factors before investing in CIMVF.

CIMVF在哪个行业运营？

Pideka Group Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth driven by increasing legalization and acceptance of cannabis for both medical and recreational use. The market is characterized by intense competition, with numerous players vying for market share. Key trends include the development of new cannabis-based products, the expansion of retail dispensaries, and the increasing consolidation of cannabis companies. Pideka Group Inc. aims to differentiate itself through its focus on pharmaceutical-grade products and its integrated supply chain. Competitors include ACNNF (Acreage Holdings Inc.), CBDNF (Charlotte's Web Holdings, Inc.), DLTNF (Delta 9 Cannabis Inc.), EEVVF (EnWave Corporation), and EPWCF (Empower Clinics Inc.).

Drug Manufacturers - Specialty & Generic

Healthcare

CIMVF有哪些增长机遇？

Expansion of cultivation and production in Colombia: Colombia offers a favorable environment for cannabis cultivation due to its climate and lower production costs. Pideka Group Inc. can leverage this advantage to increase its production capacity and reduce costs, enhancing its competitiveness in the global cannabis market. The global cannabis market is projected to reach $47 billion by 2025, providing a substantial opportunity for growth. Timeline: Ongoing.
Increased market penetration in California: California is one of the largest cannabis markets in the United States. Pideka Group Inc. can expand its presence in California by opening new dispensaries, increasing its distribution network, and developing new products tailored to the California market. The California cannabis market is projected to reach $7 billion by 2024. Timeline: Ongoing.
Development of new cannabis-based products: Pideka Group Inc. can develop new cannabis-based products, such as edibles, beverages, and topicals, to cater to evolving consumer preferences. The market for cannabis-based products is growing rapidly, driven by increasing consumer demand for alternative consumption methods. The global cannabis edibles market is projected to reach $5 billion by 2025. Timeline: Ongoing.
Strategic partnerships and acquisitions: Pideka Group Inc. can pursue strategic partnerships and acquisitions to expand its market reach, diversify its product portfolio, and gain access to new technologies. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing.
Expansion into international markets: Pideka Group Inc. can expand its operations into other international markets, such as Europe and Latin America, to capitalize on the growing global demand for cannabis products. The European cannabis market is projected to reach $3.9 billion by 2023, presenting a significant opportunity for growth. Timeline: Ongoing.

Market Cap of $0.00B indicates the company is a micro-cap stock with high growth potential but also higher risk.
P/E Ratio of -1.16 reflects the company's current lack of profitability, requiring further analysis of its future earnings potential.
Profit Margin of -2220.5% suggests significant operational challenges and the need for improved cost management.
Gross Margin of 13.1% indicates the company's ability to generate revenue from sales after accounting for the cost of goods sold, but it needs to be improved.
Beta of 0.57 suggests the stock is less volatile than the overall market, potentially offering some downside protection.

CIMVF提供哪些产品和服务？

Cultivates cannabis in Colombia.
Produces pharmaceutical-grade cannabinoids.
Manufactures decarboxylated flower.
Creates finished CBD products.
Develops finished ingredient cannabis oil.
Distributes cannabis products in California and Colombia.
Operates cannabis dispensaries in California.

CIMVF如何赚钱？

Cultivation and production of cannabis in Colombia.
Distribution and sale of cannabis products in California and Colombia.
Branding and marketing of cannabis products under the Ikanik, Essentials, Ronen, and Rations brands.

Scientific researchers requiring pharmaceutical-grade cannabinoids.
Commercial businesses utilizing cannabis oil as an ingredient.
Consumers purchasing cannabis products through dispensaries.
Patients seeking medical cannabis products.

Vertically integrated operations provide control over the supply chain.
Focus on pharmaceutical-grade cannabinoids differentiates the company from competitors.
Established presence in both California and Colombia provides access to key markets.
Brand recognition through the Ikanik, Essentials, Ronen, and Rations brands.

什么因素可能推动CIMVF股价上涨？

Upcoming: Potential changes in cannabis regulations in key markets.
Ongoing: Expansion of cultivation and production capabilities in Colombia.
Ongoing: Increased market penetration in California.
Ongoing: Development of new cannabis-based products.

CIMVF的主要风险是什么？

Potential: Intense competition from other cannabis companies.
Potential: Regulatory uncertainties and changes in cannabis laws.
Ongoing: The company's current financial instability and negative profitability.
Potential: Fluctuations in cannabis prices and market demand.
Potential: Limited access to capital and financing options.

CIMVF的核心优势是什么？

Vertically integrated operations.
Focus on pharmaceutical-grade cannabinoids.
Presence in both California and Colombia.
Established brand portfolio.

CIMVF的劣势是什么？

Negative profitability.
High operating expenses.
Limited market share.
Dependence on regulatory approvals.

CIMVF有哪些机遇？

Expansion into new markets.
Development of new products.
Strategic partnerships and acquisitions.
Increasing consumer acceptance of cannabis.

CIMVF面临哪些威胁？

Intense competition.
Regulatory uncertainties.
Fluctuations in cannabis prices.
Economic downturns.

CIMVF的竞争对手是谁？

Acreage Holdings Inc. — Focuses on the U.S. cannabis market. — (ACNNF)
Charlotte's Web Holdings, Inc. — Specializes in CBD products. — (CBDNF)
Delta 9 Cannabis Inc. — Canadian cannabis producer and retailer. — (DLTNF)
EnWave Corporation — Provides dehydration technology for cannabis processing. — (EEVVF)
Empower Clinics Inc. — Operates healthcare clinics with a focus on cannabis. — (EPWCF)

Key Metrics

MoonshotScore: 56/100

Company Profile

CEO: Borja Sanz De Madrid
Headquarters: Toronto, CA
Founded: 2021

AI Insight

AI analysis pending for CIMVF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Pideka Group Inc. do?

Pideka Group Inc., operating as Ikänik Farms, is an integrated cannabis company involved in the cultivation, production, distribution, and dispensary operations in California and Colombia. The company focuses on providing pharmaceutical-grade cannabinoids, decarboxylated flower, finished CBD products, and finished ingredient cannabis oil for scientific and commercial sales. Its vertically integrated business model allows it to control the supply chain from cultivation to retail, ensuring product quality and consistency. The company operates under the Ikanik, Essentials, Ronen, and Rations brands, targeting diverse consumer segments.

What do analysts say about CIMVF stock?

As of 2026-03-17, formal analyst ratings for CIMVF (Pideka Group Inc.) are limited due to its OTC listing and micro-cap status. However, the company's potential lies in its integrated operations and presence in key cannabis markets like California and Colombia. the may be worth researching company's negative profitability, high competition, and regulatory risks. Further research into the company's financial performance, growth strategy, and competitive landscape is recommended before making any investment decisions. The stock's beta of 0.57 suggests lower volatility compared to the broader market.

What are the main risks for CIMVF?

The main risks for Pideka Group Inc. (CIMVF) include intense competition in the cannabis industry, regulatory uncertainties surrounding cannabis legalization and compliance, and the company's current financial instability, as evidenced by its negative profit margin. As an OTC-listed stock, CIMVF also faces liquidity risks and limited access to capital. Fluctuations in cannabis prices and changes in consumer preferences could also negatively impact the company's performance. Investors should carefully assess these risks before investing in CIMVF.